Get started
Author

Mamatha Reddy Dundigalla

Observed name: MAMATHA REDDY DUNDIGALLA
Institution: Shilpa (India)
Observed institution: Shilpa (India)
ORCID: 0000-0001-8930-7153
Observed ORCID: 0000-0001-8930-7153
OpenAlex ID: A5119073059
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · World Journal of Hepatology · 6
A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia
2025 · Veerendra Kumar Panuganti, Pavan Kumar Madala, et al. · Cureus · 4
PDF
Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults
2026 · Veerendra Kumar Panuganti, Mamatha Reddy Dundigalla, et al. · Drug Design Development and Therapy · 2
PDF
Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study
2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · Advances in Pharmacological and Pharmaceutical Sciences · 2
PDF
A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial
2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · Cancer Chemotherapy and Pharmacology
Rapid Detection of Sars Cov-2 Infection in Comparision With Rt-pcr in Tertiary Care Hospital
2023 · RAJAMANICKAM VENKATA LAXMI, RAMYA A, et al. · Asian Journal of Pharmaceutical and Clinical Research
PDF
Works count: 6
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type